Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Tannock

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Nature Reviews. Clinical Oncology|April 21, 2018
The paradox of precision medicineJonathan Kimmelman, Ian Tannock
Critical Reviews in Oncology/Hematology|August 7, 2007
Cognitive function after chemotherapy in adults with solid tumoursJanette Vardy, Ian Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?Christopher M Booth, Ian Tannock
BMC Cancer|July 6, 2016
Use and misuse of common terminology criteria for adverse events in cancer clinical trialsSheng Zhang, Fei Liang, Ian Tannock
Endocrine-Related Cancer|April 20, 2011
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancerThierry Petit, Patrick Dufour, Ian Tannock
The New England Journal of Medicine|January 6, 2010
Treatment of lung cancerBostjan Seruga, Eitan Amir, Ian Tannock
Neuropharmacology|August 2, 2011
Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse modelGordon Winocur, Malcolm A Binns, Ian Tannock
Journal of the National Cancer Institute|May 27, 2016
Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical TrialsSheng Zhang, Fei Liang, Wenfeng Li, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Value-Added Decisions in OncologyIan Tannock, Carolyn J Presley, Leonard B Saltz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?Eitan Amir, Bostjan Seruga, Orit Freedman, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Nature Reviews. Clinical Oncology|April 21, 2018
The paradox of precision medicineJonathan Kimmelman, Ian Tannock
Critical Reviews in Oncology/Hematology|August 7, 2007
Cognitive function after chemotherapy in adults with solid tumoursJanette Vardy, Ian Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?Christopher M Booth, Ian Tannock
BMC Cancer|July 6, 2016
Use and misuse of common terminology criteria for adverse events in cancer clinical trialsSheng Zhang, Fei Liang, Ian Tannock
Endocrine-Related Cancer|April 20, 2011
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancerThierry Petit, Patrick Dufour, Ian Tannock
The New England Journal of Medicine|January 6, 2010
Treatment of lung cancerBostjan Seruga, Eitan Amir, Ian Tannock
Neuropharmacology|August 2, 2011
Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse modelGordon Winocur, Malcolm A Binns, Ian Tannock
Journal of the National Cancer Institute|May 27, 2016
Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical TrialsSheng Zhang, Fei Liang, Wenfeng Li, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Value-Added Decisions in OncologyIan Tannock, Carolyn J Presley, Leonard B Saltz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?Eitan Amir, Bostjan Seruga, Orit Freedman, et al.
Pageof 5